Carrie House, PhDSan Diego State University Research FoundationSan Diego, CA Role of Macrophages in the Development of Drug-Resistant Ovarian Cancer Stem Cells Following Chemotherapy Ovarian cancer is the deadliest gynecological cancer in the United States and is associated with a high rate of recurrence. Unfortunately, tumors that grow back stop responding to chemotherapy and become […]
Read More
Priyanka Verma, PhDWashington University, St. Louis2022 MCM Pilot Study Award Targeting drug resistance in BRCA-mutant ovarian cancers by exploiting endogenous base damage Many ovarian cancers are caused by mutations in proteins that usually function to repair DNA damage. These cancer cells with accumulated DNA damage are targeted by PARP inhibitor therapies. Despite ovarian tumors showing […]
Read More
Hector Franco, PhDUniversity of North Carolina, Chapel Hill2022 Lester and Bernice Smith Pilot Study Award Identifying Drivers of Therapeutic Resistance in Ovarian Cancer at Single-Cell Resolution Ovarian cancer is one of the deadliest cancers among women worldwide. Most women respond well to the standard treatment; however, up to 75% of these patients experience a recurrence […]
Read More
Toni Antalis, PhDUniversity of Maryland, Baltimore2022 Rosser Family Pilot Study Award Emerging roles of MASP activation in ovarian cancer metastasis and acquired chemoresistance While ovarian cancer responds well to initial treatments, it frequently returns due to acquired chemotherapy resistance. Although chemotherapies aim slow or stop tumor growth, cancer cells continue to evolve between chemotherapy cycles. […]
Read More
Novel approaches to target MYC in ovarian cancer Many ovarian cancers express the cancer-causing MYC protein at unusually high levels. The activation of MYC is a hallmark of cancer initiation, progression, and resistance to therapy. Unfortunately, MYC is one of the most difficult proteins to target therapeutically. Development of an effective therapy against MYC activity […]
Read More
Multimodal single-cell surfaceome and transcriptome profiling of longitudinal high-grade ovarian cancer ascites samples Despite advances in the initial treatment of high-grade serous ovarian cancer (HGSOC), recurrence of the disease is very common and effective treatment of recurrent HGSOC remains a major challenge. In order for a tumor to gain resistance to chemotherapy and progress into […]
Read More
Nerves as novel actors in the tumor microenvironment: the role of exosomes in ovarian cancer tumor innervation Although advances in surgery and chemotherapy for ovarian cancer have improved survival, most women with ovarian cancer will experience recurrence of their disease. Unfortunately, recurrent ovarian cancers respond poorly to chemotherapy and are incurable, highlighting the need for […]
Read More
Tao Wu, PhDBaylor College of Medicine2020 Scientific Scholar Award Targeting Epigenetic Landscape Reprogramming to Combat Drug-resistance in Ovarian Cancer Despite major improvements in therapeutic approaches to ovarian cancer, the ability of tumors to develop resistance to anti-cancer drugs remains the major challenge in achieving longer-lasting remission. One of the ways drug resistance is thought to […]
Read More
Joe Delaney, PhDMedical University of South Carolina2020 Pilot Study Award Slowing ovarian cancer evolution by LINE-1 inhibition High grade serous ovarian cancer is unique from other cancer types in that it has high levels of a type of DNA called LINE-1 elements. LINE-1 elements are known as selfish DNA because they can make copies of […]
Read More
Matthew Wakefield, PhDThe Walter & Eliza Hall Institute of Medical Research2020 Rosser Family Pilot Study Award Identifying all mutations in the PARP1 catalytic domain that impact PARP inhibitor action PARP inhibitors are a class of drugs that are becoming a major part of treatment for high grade ovarian cancer. These drugs kill cancer cells by […]
Read More